Supplemental Figure 4 from Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma

S4. Moderate doses of cisplatin and anti-PD-1 do not cause significant kidney toxicity or hearing loss. A, kidneys were harvested from MOC1 tumor-bearing mice upon euthanasia, sectioned, and stained with H&E. Examples shown are representative of at least three different animals per treatment group. B and C, hearing was assessed in control or cisplatin-treated, MOC1 tumor-bearing mice after 6 weeks of treatment by measuring auditory brainstem response thresholds (B) and distortion product otoacoustic emission amplitudes (C). Data are mean (B) {plus minus} SEM (C) from two mice per group.